Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Forced Expiratory Volume

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    637 result(s) found for: Forced Expiratory Volume. Displaying page 1 of 32.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2011-001824-39 Sponsor Protocol Number: CMID001A2201 Start Date*: 2013-05-08
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomized, double-blind, double-dummy, placebo-controlled, 3-period crossover study to evaluate the pharmacodynamics, pharmacokinetics, safety and tolerability of orally inhaled indacaterol admi...
    Medical condition: Persistent Asthma
    Disease: Version SOC Term Classification Code Term Level
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10038738 Respiratory, thoracic and mediastinal disorders SOC
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2011-001777-43 Sponsor Protocol Number: 205.446 Start Date*: 2012-05-15
    Sponsor Name:Boehringer Ingelheim RCV GmbH & Co KG
    Full Title: A randomised, double-blind, placebo-controlled, parallel-group trial to evaluate efficacy and safety of tiotropium inhalation solution (2.5 µg and 5 µg) delivered via Respimat® inhaler once daily i...
    Medical condition: Severe persistent asthma
    Disease: Version SOC Term Classification Code Term Level
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10003560 Asthma NOS LLT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: LV (Completed) LT (Completed) DE (Completed) BE (Completed) CZ (Completed) HU (Completed) PL (Completed) SK (Completed) RO (Completed) BG (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2004-001888-21 Sponsor Protocol Number: DPM-CF-203 Start Date*: 2004-12-03
    Sponsor Name:Pharmaxis Ltd
    Full Title: A cross-over comparative study of inhaled mannitol, alone and in combination with daily rhDNase, in children with cystic fibrosis
    Medical condition: Cystic fibrosis (CF)
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2006-002484-99 Sponsor Protocol Number: 2006 Start Date*: 2007-01-10
    Sponsor Name:South Devon Health Care NHS Foundation Trust
    Full Title: The Use of Nebulised Magnesium Sulphate in Exacerbations of Chronic Obstructive Pulmonary Disease (COPD)
    Medical condition: We propose a study to examine whether adjuvant magnesium therapy administered via nebuliser is effective in the management of patients with acute exacerbations of COPD. The findings should help to ...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-004818-28 Sponsor Protocol Number: CNVA237A2320 Start Date*: 2015-07-13
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomized, double-blind, parallel group, 26-week study evaluating the efficacy, safety and tolerability of NVA237 given once or twice daily, in patients with moderate and severe chronic obstruct...
    Medical condition: Chronic Obstructive Pulmonary Disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004855 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FI (Completed) HU (Completed) BE (Completed) SE (Completed) GB (Completed) BG (Completed) PL (Completed) RO (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-001758-26 Sponsor Protocol Number: 205.445 Start Date*: 2012-05-15
    Sponsor Name:Boehringer
    Full Title: A randomised, double-blind, placebo-controlled, parallel-group trial to evaluate efficacy and safety of tiotropium inhalation solution (2.5 µg and 5 µg) delivered via Respimat® inhaler once daily i...
    Medical condition: Moderate persisten asthma
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004855 10003560 Asthma NOS LLT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: LV (Completed) LT (Completed) PT (Completed) DE (Completed) BG (Completed) SE (Completed) HU (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2005-003893-46 Sponsor Protocol Number: NA Start Date*: 2009-11-03
    Sponsor Name:KULeuven and University Hospitals Leuven (Leuven Lung Transplant Group)
    Full Title: AZITHROMYCIN IN BRONCHIOLITIS OBLITERANS SYNDROME
    Medical condition: - Chronic rejection at 1 and 2 year post-lung transplantation - Mortality at 1 and 2 year post-lung transplantation - Acute rejection rate at 1 and 2 post-lung transplantation - Infection rate at 1...
    Disease: Version SOC Term Classification Code Term Level
    12.0 10029888 Obliterative bronchiolitis LLT
    12.0 10049202 Bronchiolitis obliterans LLT
    12.0 10068805 Follicular bronchiolitis LLT
    12.0 10019319 Heart-lung transplant rejection LLT
    12.0 10025127 Lung transplant LLT
    12.0 10050433 Prophylaxis against lung transplant rejection LLT
    12.0 10050437 Prophylaxis against heart and lung transplant rejection LLT
    12.0 10051604 Lung transplant rejection LLT
    12.0 10056409 Heart and lung transplant LLT
    12.0 10016547 FEV LLT
    12.0 10016549 FEV 1 abnormal LLT
    12.0 10016550 FEV 1 decreased LLT
    12.0 10016553 FEV 1 low LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2010-021983-14 Sponsor Protocol Number: MLK002 Start Date*: 2010-09-23
    Sponsor Name:UZ Gasthuisberg
    Full Title: A randomized placebo-controlled double blind study to treat BOS.
    Medical condition: -Mortality at 1 and 2 year post diagnosis of BOS -Infection rate during BOS -Evolution of pulmonary function after diagnosis of BOS
    Disease: Version SOC Term Classification Code Term Level
    12.1 10029888 Obliterative bronchiolitis LLT
    12.1 10049202 Bronchiolitis obliterans LLT
    12.1 10068805 Follicular bronchiolitis LLT
    12.1 10019319 Heart-lung transplant rejection LLT
    12.1 10025127 Lung transplant LLT
    12.1 10051604 Lung transplant rejection LLT
    12.1 10056409 Heart and lung transplant LLT
    12.1 10016547 FEV LLT
    12.1 10016549 FEV 1 abnormal LLT
    12.1 10016550 FEV 1 decreased LLT
    12.1 10016553 FEV 1 low LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2010-022027-30 Sponsor Protocol Number: VIT001 Start Date*: 2010-09-23
    Sponsor Name:UZ Gasthuisberg
    Full Title: A randomized placebo-controlled double blind study to prevent BOS
    Medical condition: A study to prevent the occurence of chronic rejection after lung transplantation. Other points of investigation include lung function evolution, rate of survival, BAL cellularity, infection rate, r...
    Disease: Version SOC Term Classification Code Term Level
    12.1 10029888 Obliterative bronchiolitis LLT
    12.1 10049202 Bronchiolitis obliterans LLT
    12.1 10068805 Follicular bronchiolitis LLT
    12.1 10019319 Heart-lung transplant rejection LLT
    12.1 10025127 Lung transplant LLT
    12.1 10050433 Prophylaxis against lung transplant rejection LLT
    12.1 10050437 Prophylaxis against heart and lung transplant rejection LLT
    12.1 10051604 Lung transplant rejection LLT
    12.1 10056409 Heart and lung transplant LLT
    12.1 10016547 FEV LLT
    12.1 10016549 FEV 1 abnormal LLT
    12.1 10016550 FEV 1 decreased LLT
    12.1 10016553 FEV 1 low LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-006693-24 Sponsor Protocol Number: Moli1901-010B Start Date*: 2007-05-09
    Sponsor Name:AOP Orphan Pharmaceuticals AG
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Dose-finding Study to Evaluate the Efficacy and Safety of Aerosolized Moli1901 in Adolescents (12 Years of Age or Older) and Adults with Cystic Fibrosis
    Medical condition: Cystic fibrosis is the most common fatal inherited disease in the Caucasian population, affecting about 4 in 10.000 children. In cystic fibrosis chloride transport across the respiratory epithelium...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10011763 Cystic fibrosis lung PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) CZ (Completed) FR (Completed) DE (Completed) HU (Completed) SE (Completed) ES (Completed) PL (Ongoing) IT (Completed)
    Trial results: View results
    EudraCT Number: 2011-003066-32 Sponsor Protocol Number: CQBX258X2201 Start Date*: 2012-02-09
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomized double-blind multiple-dose placebo-controlled trial to establish the efficacy of QBX258 (combination of VAK694 and QAX576) in asthma that is inadequately controlled with inhaled cortic...
    Medical condition: Patients with asthma that are inadequately controlled with inhaled corticosteroids and long acting beta agonists
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004855 10049106 Asthma chronic LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2021-005495-19 Sponsor Protocol Number: pro.LISA_01_21 Start Date*: 2022-01-19
    Sponsor Name:University Hospital Schleswig-Holstein
    Full Title: A randomized controlled trial in preterm infants comparing prophylactic with selective “Less Invasive Surfactant Administration” (PRO-LISA)
    Medical condition: Respiratory distress syndrome of premature infants
    Disease:
    Population Age: Preterm newborn infants, Under 18 Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-007073-75 Sponsor Protocol Number: 07-01/DPI Fluticason_250 Start Date*: 2008-01-30
    Sponsor Name:mibe GmbH Arzneimittel
    Full Title: Randomised, double-blind, double-dummy, parallel trial comparing a novel DPI with 250 µg fluticasone versus Flutide® 250 Diskus® in patients with persistent asthma
    Medical condition: Persistent Asthma in adults
    Disease: Version SOC Term Classification Code Term Level
    9.1 10049106 Asthma chronic LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2016-004318-82 Sponsor Protocol Number: CTBM100CUS03 Start Date*: 2017-05-15
    Sponsor Name:Novartis Pharmaceuticals Corporation
    Full Title: Tobramycin Inhalation Powder (TIP) Administered Once Daily Continuously Versus TIP Administered BID in 28 Day on / 28 Day Off Cycles
    Medical condition: Cystic Fibrosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10011762 Cystic fibrosis PT
    20.0 100000004862 10021860 Infection Pseudomonas aeruginosa LLT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2016-001696-79 Sponsor Protocol Number: KH176-201 Start Date*: 2016-09-06
    Sponsor Name:Khondrion BV
    Full Title: A double-blind, randomized, placebo-controlled, single-center, two-way cross-over study with KH176 in patients with the mitochondrial DNA tRNALeu(UUR) m.3243A>G mutation and clinical signs of mitoc...
    Medical condition: Inherited mitochondrial disease, including MELAS (mitochondrial Encephalopathy Lactic Acidosis and Stroke like episodes) and MIDD (Maternally Inherited Diabetes and Deafness)
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-005469-12 Sponsor Protocol Number: NEO-012 Start Date*: 2006-01-06
    Sponsor Name:Neolab Limited
    Full Title: A Phase III, randomised, double-blind, double-dummy cross-over study to compare two dry powder inhaled formulations of budesonide on methacholine hyper-reactivity in patients with stable, persisten...
    Medical condition: Stable, persistent, moderate asthma
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-004920-39 Sponsor Protocol Number: 38518168ASH2001 Start Date*: 2013-08-16
    Sponsor Name:Janssen-Cilag International N.V.
    Full Title: A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel Group Study of JNJ-38518168 in Symptomatic Adult Subjects with Uncontrolled, Persistent Asthma
    Medical condition: Asthma
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004855 10068462 Eosinophilic asthma LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2014-005125-12 Sponsor Protocol Number: LIRALUNG Start Date*: 2016-05-12
    Sponsor Name:Dr. Albert Lecube, Ph.D., M.D.
    Full Title: MULTICENTRE RANDOMIZED DOUBLE BLIND, CROSSOVER, PLACEBO-CONTROLLED CLINICAL TRIAL TO EVALUATE THE EFFECT OF LIRAGLUTIDE ON LUNG FUNCTION IN PATIENTS WITH TYPE 2 DIABETES MELLITUS (LIRALUNG STUDY)
    Medical condition: Type 2 Diabetes
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-003289-29 Sponsor Protocol Number: ACT15102 Start Date*: 2018-06-19
    Sponsor Name:Sanofi-aventis recherche & développement
    Full Title: A Randomized, Double-blind, Placebo-controlled, Parallel-group, 12-week Proof-of-Concept (PoC) Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500 and the Coadministration...
    Medical condition: Asthma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed)
    Trial results: View results
    EudraCT Number: 2017-004279-30 Sponsor Protocol Number: SNT-III-012-E Start Date*: 2018-06-14
    Sponsor Name:Santhera Pharmaceuticals (Switzerland) Limited
    Full Title: A Phase III Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of Idebenone in Patients with Duchenne Muscular Dystrophy (DMD) who completed the SIDEROS study
    Medical condition: Duchenne Muscular Dystrophy (DMD)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10013801 Duchenne muscular dystrophy PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male
    Trial protocol: BE (Completed) GB (Prematurely Ended) FR (Ongoing) SE (Prematurely Ended) NL (Prematurely Ended) DE (Prematurely Ended) ES (Prematurely Ended) AT (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 20 00:20:47 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA